A study evaluating the effects of the combination of recombinant humanized monoclonal antibody (rhumAb)HER2, an anti-HER2 antibody, with 4 Gy irradiation by x-rays demonstrated that combined treatment enhanced growth inhibition effects in HNSCC cell lines when compared with rhumAbHER2 or irradiation alone (105). Here, ERBB2 is linked to head and neck squamous cell carcinoma.